Savings from single vendor CDMOs put at $45 million by Tufts study

A new study comparing the economic impacts of varying contract manufacturing approaches has found that a single-source outsourcing model shortens the drug development cycle, providing sponsors with substantial financial gains from having their products reach the market sooner.

The modeling study, conducted by The Tufts Center for the Study of Drug Development (CSDD) and supported by a grant from the US biotech product development company, Thermo Fisher Scientific (NYSE: TMO), is entitled Assessing the Economics of Single-Source vs Multi-Vendor Manufacturing.

Joseph DiMasi, director of economic analysis at Tufts CSDD and principal investigator for the study, said: “Drug development costs continue to rise despite ongoing efforts across the breadth of pharmaceutical and biotech companies to curtail spending.